

# Joan Clria

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9256449/joan-claria-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

152  
papers

12,905  
citations

53  
h-index

112  
g-index

163  
ext. papers

15,120  
ext. citations

6.8  
avg. IF

5.9  
L-index

#	Paper	IF	Citations
152	Reduced Plasma Extracellular Vesicle CD5L Content in Patients With Acute-On-Chronic Liver Failure: Interplay With Specialized Pro-Resolving Lipid Mediators.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 842996	8.4	1
151	Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. <i>Gut</i> , <b>2021</b> , 70, 379-387	19.2	32
150	Mitochondrial Dysfunction in Advanced Liver Disease: Emerging Concepts. <i>Frontiers in Molecular Biosciences</i> , <b>2021</b> , 8, 772174	5.6	1
149	La aplicaci3n de las t3cnicas para comprender la base molecular de la insuficiencia hep3tica aguda sobre cr3nica. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , <b>2021</b> , 2, 528-540	1.3	
148	Hepatic inflammasome activation as origin of Interleukin-1 $\beta$ and Interleukin-1 $\gamma$ in liver cirrhosis. <i>Gut</i> , <b>2021</b> , 70, 1799-1800	19.2	5
147	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1097-1108	13.4	41
146	Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1117-1131	13.4	11
145	The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 670-685	13.4	50
144	Albumin protects the liver from tumor necrosis factor $\beta$ -induced immunopathology. <i>FASEB Journal</i> , <b>2021</b> , 35, e21365	0.9	4
143	Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 1116-1127	13.4	5
142	Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. <i>Journal of Hepatology</i> , <b>2021</b> , 75 Suppl 1, S49-S66	13.4	25
141	Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	10
140	Proresolving lipid mediators and liver disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2021</b> , 1866, 159023	5	5
139	Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure. <i>Cells</i> , <b>2020</b> , 9,	7.9	13
138	Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure. <i>Cells</i> , <b>2020</b> , 9,	7.9	30
137	Albumin in decompensated cirrhosis: new concepts and perspectives. <i>Gut</i> , <b>2020</b> , 69, 1127-1138	19.2	70
136	The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1352	8.4	6

135	HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 113-120	13.4	29
134	Genetic variants of innate immunity receptors are associated with mortality in cirrhotic patients with bacterial infection. <i>Liver International</i> , <b>2020</b> , 40, 646-653	7.9	5
133	Liver Failure, Acute-on-Chronic <b>2020</b> , 436-443		1
132	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 688-701	13.4	102
131	Anti-Inflammatory and Proresolving Effects of the Omega-6 Polyunsaturated Fatty Acid Adrenic Acid. <i>Journal of Immunology</i> , <b>2020</b> , 205, 2840-2849	5.3	8
130	Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	22
129	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 842-854	13.4	108
128	Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 980-982	13.4	4
127	Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner. <i>FASEB Journal</i> , <b>2020</b> , 34, 10640-10656	0.9	24
126	Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP/NF-B/NLRP3 inflammasome circuit. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 28263-28274	11.5	9
125	Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 963-973.e14	6.9	38
124	Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 817-828	13.4	19
123	Characterization of Blood Immune Cells in Patients With Decompensated Cirrhosis Including ACLF. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 619039	8.4	9
122	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. <i>Gastroenterology</i> , <b>2019</b> , 157, 149-162	13.3	91
121	Leukocytes from obese individuals exhibit an impaired SPM signature. <i>FASEB Journal</i> , <b>2019</b> , 33, 7072-7083	8.9	22
120	Compartmentalization of Immune Response and Microbial Translocation in Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 69	8.4	23
119	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 476	8.4	76
118	Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis. <i>PLoS ONE</i> , <b>2019</b> , 14, e0222840	3.7	2

117	The G-protein coupled receptor ChemR23 determines smooth muscle cell phenotypic switching to enhance high phosphate-induced vascular calcification. <i>Cardiovascular Research</i> , <b>2019</b> , 115, 1557-1566	9.9	24
116	Orchestration of Tryptophan-Kynurenine Pathway, Acute Decompensation, and Acute-on-Chronic Liver Failure in Cirrhosis. <i>Hepatology</i> , <b>2019</b> , 69, 1686-1701	11.2	45
115	Frontline Science: Specialized proresolving lipid mediators inhibit the priming and activation of the macrophage NLRP3 inflammasome. <i>Journal of Leukocyte Biology</i> , <b>2019</b> , 105, 25-36	6.5	50
114	The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis. <i>British Journal of Pharmacology</i> , <b>2018</b> , 175, 953-967	8.6	33
113	Oxidized Albumin Triggers a Cytokine Storm in Leukocytes Through P38 Mitogen-Activated Protein Kinase: Role in Systemic Inflammation in Decompensated Cirrhosis. <i>Hepatology</i> , <b>2018</b> , 68, 1937-1952	11.2	32
112	Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality. <i>Liver International</i> , <b>2018</b> , 38, 875-884	7.9	23
111	Opposing Effects on Vascular Smooth Muscle Cell Proliferation and Macrophage-induced Inflammation Reveal a Protective Role for the Proresolving Lipid Mediator Receptor ChemR23 in Intimal Hyperplasia. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 1327	5.6	17
110	Systemic Inflammation and Acute-on-Chronic Liver Failure: Too Much, Not Enough. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2018</b> , 2018, 1027152	2.8	31
109	Pro-resolving actions of SPM in adipose tissue biology. <i>Molecular Aspects of Medicine</i> , <b>2017</b> , 58, 83-92	16.7	27
108	The specialized proresolving lipid mediator maresin 1 protects hepatocytes from lipotoxic and hypoxia-induced endoplasmic reticulum stress. <i>FASEB Journal</i> , <b>2017</b> , 31, 5384-5398	0.9	40
107	Association of a variant in the gene encoding for ERV1/ChemR23 with reduced inflammation in visceral adipose tissue from morbidly obese individuals. <i>Scientific Reports</i> , <b>2017</b> , 7, 15724	4.9	22
106	Polymorphisms in the IL-1 gene cluster influence systemic inflammation in patients at risk for acute-on-chronic liver failure. <i>Hepatology</i> , <b>2017</b> , 65, 202-216	11.2	28
105	Role of bioactive lipid mediators in obese adipose tissue inflammation and endocrine dysfunction. <i>Molecular and Cellular Endocrinology</i> , <b>2016</b> , 419, 44-59	4.4	54
104	Principles, Mechanisms of Action, and Future Prospects of Anti-inflammatory Drugs <b>2016</b> , 17-34		3
103	Signaling and Immunoresolving Actions of Resolvin D1 in Inflamed Human Visceral Adipose Tissue. <i>Journal of Immunology</i> , <b>2016</b> , 197, 3360-3370	5.3	63
102	The Acute-on-Chronic Liver Failure Syndrome, or When the Innate Immune System Goes Astray. <i>Journal of Immunology</i> , <b>2016</b> , 197, 3755-3761	5.3	72
101	Pro-resolving mediators produced from EPA and DHA: Overview of the pathways involved and their mechanisms in metabolic syndrome and related liver diseases. <i>European Journal of Pharmacology</i> , <b>2016</b> , 785, 133-143	5.3	60
100	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , <b>2016</b> , 12, 1-222	10.2	3838

99	Prostaglandin E2 Exerts Multiple Regulatory Actions on Human Obese Adipose Tissue Remodeling, Inflammation, Adaptive Thermogenesis and Lipolysis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0153751	3.7	69
98	Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. <i>Gut</i> , <b>2016</b> , 65, 1535-45	19.2	62
97	Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. <i>Hepatology</i> , <b>2016</b> , 64, 1249-64	11.2	349
96	Aplicaci3n de la secuenciaci3n masiva de nueva generaci3n al diagn3stico molecular de la hipercolesterolemia familiar. <i>Revista Del Laboratorio Cl3nico</i> , <b>2015</b> , 8, 8-18	0	
95	Aspirin in the 21st century-common mechanisms of disease and their modulation by aspirin: a report from the 2015 scientific conference of the international aspirin foundation, 28 August, London, UK. <i>Ecancermedicalscience</i> , <b>2015</b> , 9, 581	2.7	4
94	Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: role for omega-3 epoxides. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 536-41	11.5	146
93	Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. <i>Cell Metabolism</i> , <b>2014</b> , 19, 21-36	24.6	291
92	Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis. <i>FASEB Journal</i> , <b>2014</b> , 28, 836-48	0.9	72
91	Molecular interplay between $\delta/6$ desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. <i>Gut</i> , <b>2014</b> , 63, 344-55	19.2	88
90	Prostaglandin E2 signals white-to-brown adipogenic differentiation. <i>Adipocyte</i> , <b>2014</b> , 3, 290-6	3.2	21
89	Coordinate functional regulation between microsomal prostaglandin E synthase-1 (mPGES-1) and peroxisome proliferator-activated receptor $\alpha$ (PPAR $\alpha$ ) in the conversion of white-to-brown adipocytes. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 28230-42	5.4	55
88	Omega-3-derived mediators counteract obesity-induced adipose tissue inflammation. <i>Prostaglandins and Other Lipid Mediators</i> , <b>2013</b> , 107, 77-84	3.7	28
87	Cell-specific PPAR $\alpha$ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 1045-53	13.4	62
86	Diversity of lipid mediators in human adipose tissue depots. <i>American Journal of Physiology - Cell Physiology</i> , <b>2013</b> , 304, C1141-9	5.4	98
85	Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. <i>Journal of Immunology</i> , <b>2012</b> , 189, 2597-605	5.3	179
84	Natural killer cell recognition and killing of activated hepatic stellate cells. <i>Gut</i> , <b>2012</b> , 61, 792-3	19.2	6
83	An investigation of the resolution of inflammation (catabasis) in COPD. <i>Respiratory Research</i> , <b>2012</b> , 13, 101	7.3	15
82	Resolution of inflammation in obesity-induced liver disease. <i>Frontiers in Immunology</i> , <b>2012</b> , 3, 257	8.4	51

81	New insights into the role of macrophages in adipose tissue inflammation and Fatty liver disease: modulation by endogenous omega-3 Fatty Acid-derived lipid mediators. <i>Frontiers in Immunology</i> , <b>2011</b> , 2, 49	8.4	34
80	The 5-lipoxygenase/leukotriene pathway in obesity, insulin resistance, and fatty liver disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , <b>2011</b> , 14, 347-53	3.8	44
79	Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. <i>Journal of Immunology</i> , <b>2011</b> , 187, 5408-18	5.3	306
78	Role for PPAR $\alpha$ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. <i>FASEB Journal</i> , <b>2011</b> , 25, 2538-50	0.9	276
77	The Role of Inflammatory Mediators in Liver Failure <b>2011</b> , 131-153		4
76	Resolution of adipose tissue inflammation. <i>Scientific World Journal, The</i> , <b>2010</b> , 10, 832-56	2.2	46
75	5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. <i>Journal of Immunology</i> , <b>2010</b> , 184, 3978-87	5.3	111
74	Resolvins, protectins and other lipid mediators in obesity-associated inflammatory disorders. <i>Drug Discovery Today Disease Mechanisms</i> , <b>2010</b> , 7, e219-e225		1
73	Protection from hepatic lipid accumulation and inflammation by genetic ablation of 5-lipoxygenase. <i>Prostaglandins and Other Lipid Mediators</i> , <b>2010</b> , 92, 54-61	3.7	18
72	5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice. <i>Hepatology</i> , <b>2010</b> , 51, 817-27	11.2	70
71	Disruption of the 12/15-lipoxygenase gene (Alox15) protects hyperlipidemic mice from nonalcoholic fatty liver disease. <i>Hepatology</i> , <b>2010</b> , 52, 1980-91	11.2	46
70	The pathogen receptor liver and lymph node sinusoidal endothelial cell C-type lectin is expressed in human Kupffer cells and regulated by PU.1. <i>Hepatology</i> , <b>2009</b> , 49, 287-96	11.2	32
69	Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. <i>FASEB Journal</i> , <b>2009</b> , 23, 1946-57	0.9	448
68	Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols. <i>American Journal of Physiology - Renal Physiology</i> , <b>2009</b> , 296, G553-62	5.1	57
67	Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice. <i>Journal of Lipid Research</i> , <b>2008</b> , 49, 2513-23	6.3	36
66	Bradykinin attenuates hepatocellular damage and fibrosis in rats with chronic liver injury. <i>Gastroenterology</i> , <b>2007</b> , 133, 2019-28	13.3	28
65	Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2007</b> , 323, 778-86	4.7	49
64	New approaches to the modulation of the cyclooxygenase-2 and 5-lipoxygenase pathways. <i>Current Topics in Medicinal Chemistry</i> , <b>2007</b> , 7, 297-309	3	48

63	The results in rodent models of atherosclerosis are not interchangeable: the influence of diet and strain. <i>Atherosclerosis</i> , <b>2007</b> , 195, e85-92	3.1	50
62	Changes in liver and plasma acetylcholinesterase in rats with cirrhosis induced by bile duct ligation. <i>Hepatology</i> , <b>2006</b> , 43, 444-53	11.2	34
61	New insights into the regulation of liver inflammation and oxidative stress. <i>Mini-Reviews in Medicinal Chemistry</i> , <b>2006</b> , 6, 1321-30	3.2	23
60	Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. <i>FASEB Journal</i> , <b>2006</b> , 20, 2537-9	0.9	171
59	Gene expression profiling of renal dysfunction in rats with experimental cirrhosis. <i>Journal of Hepatology</i> , <b>2006</b> , 45, 221-9	13.4	3
58	Regulation of cell proliferation and apoptosis by bioactive lipid mediators. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , <b>2006</b> , 1, 369-82	2.6	24
57	A coding polymorphism in the 12-lipoxygenase gene is associated to essential hypertension and urinary 12(S)-HETE. <i>Kidney International</i> , <b>2006</b> , 69, 526-30	9.9	27
56	The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARgamma. Influence of albumin. <i>Journal of Hepatology</i> , <b>2005</b> , 42, 75-81	13.4	32
55	Liver: the formation and actions of aspirin-triggered lipoxins. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , <b>2005</b> , 73, 277-82	2.8	12
54	Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. <i>Hepatology</i> , <b>2005</b> , 41, 579-87	11.2	58
53	Reply:. <i>Hepatology</i> , <b>2005</b> , 42, 238-238	11.2	5
52	Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. <i>Current Pharmaceutical Design</i> , <b>2005</b> , 11, 3431-47	3.3	77
51	The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation. <i>FASEB Journal</i> , <b>2005</b> , 19, 1120-2	0.9	118
50	Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells. <i>Journal of Leukocyte Biology</i> , <b>2005</b> , 78, 871-8	6.5	50
49	5-Lipoxygenase (5-LO) is Involved in Kupffer Cell Survival. Possible Role of 5-LO Products in the Pathogenesis of Liver Fibrosis. <i>Comparative Hepatology</i> , <b>2004</b> , 3 Suppl 1, S19		3
48	F2 isoprostane is already increased at the onset of type 1 diabetes mellitus: effect of glycemic control. <i>Metabolism: Clinical and Experimental</i> , <b>2004</b> , 53, 1118-20	12.7	28
47	Increased apoptosis dependent on caspase-3 activity in polymorphonuclear leukocytes from patients with cirrhosis and ascites. <i>Journal of Hepatology</i> , <b>2004</b> , 41, 44-8	13.4	23
46	Cyclooxygenase-2 biology. <i>Current Pharmaceutical Design</i> , <b>2003</b> , 9, 2177-90	3.3	176

45	Prostaglandins and other cyclooxygenase-dependent arachidonic acid metabolites and the kidney in liver disease. <i>Prostaglandins and Other Lipid Mediators</i> , <b>2003</b> , 72, 19-33	3.7	16
44	Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. <i>FASEB Journal</i> , <b>2003</b> , 17, 1986-95	0.9	185
43	Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis. <i>FASEB Journal</i> , <b>2003</b> , 17, 1745-7	0.9	59
42	Renal effects of selective cyclooxygenase inhibition in experimental liver disease. <i>Advances in Experimental Medicine and Biology</i> , <b>2003</b> , 525, 133-6	3.6	
41	Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. <i>British Journal of Pharmacology</i> , <b>2002</b> , 135, 891-900	8.6	35
40	Aspirin (ASA) regulates 5-lipoxygenase activity and peroxisome proliferator-activated receptor alpha-mediated CINC-1 release in rat liver cells: novel actions of lipoxin A4 (LXA4) and ASA-triggered 15-epi-LXA4. <i>FASEB Journal</i> , <b>2002</b> , 16, 1937-9	0.9	52
39	Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. <i>Gastroenterology</i> , <b>2002</b> , 122, 85-93	13.3	183
38	5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. <i>Gastroenterology</i> , <b>2002</b> , 122, 387-93	13.3	87
37	Aspirin-triggered 15-epi-lipoxin A4 biosynthesis in rat liver cells. <i>Advances in Experimental Medicine and Biology</i> , <b>2002</b> , 507, 199-209	3.6	
36	Increased levels of 12(S)-HETE in patients with essential hypertension. <i>Hypertension</i> , <b>2001</b> , 37, 334-8	8.5	74
35	5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. <i>FASEB Journal</i> , <b>2001</b> , 15, 2326-36	0.9	106
34	Sodium in preascitic cirrhosis: please pass the salt. <i>Gut</i> , <b>2001</b> , 49, 748-9	19.2	
33	Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. <i>Gastroenterology</i> , <b>2000</b> , 119, 794-805	13.3	60
32	Hepatocytes are a rich source of novel aspirin-triggered 15-epi-lipoxin A(4). <i>American Journal of Physiology - Cell Physiology</i> , <b>1999</b> , 277, C870-7	5.4	42
31	Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: regulation by cytokines and bacterial lipopolysaccharide. <i>Hepatology</i> , <b>1999</b> , 29, 1057-63	11.2	59
30	Atrial natriuretic peptide antagonizes endothelin-induced calcium increase and cell contraction in cultured human hepatic stellate cells. <i>Hepatology</i> , <b>1999</b> , 30, 501-9	11.2	26
29	Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. <i>Gastroenterology</i> , <b>1999</b> , 116, 1167-75	13.3	50
28	Smoking increases serum levels of transforming growth factor-beta in diabetic patients. <i>Diabetes Care</i> , <b>1999</b> , 22, 1915-6	14.6	25



27	Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites. <i>Gastroenterology</i> , <b>1998</b> , 115, 147-56	13.3	53
26	Aspirin-Triggered Lipoxins (15-epi-LX) Are Generated by the Human Lung Adenocarcinoma Cell Line (A549) Neutrophil Interactions and Are Potent Inhibitors of Cell Proliferation. <i>Molecular Medicine</i> , <b>1996</b> , 2, 583-596	6.2	162
25	Endothelin 1 does not play a major role in the homeostasis of arterial pressure in cirrhotic rats with ascites. <i>Gastroenterology</i> , <b>1995</b> , 108, 1842-8	13.3	53
24	Aquaretic effect of the kappa-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. <i>Gastroenterology</i> , <b>1995</b> , 109, 217-23	13.3	40
23	Nitric oxide production in arterial vessels of cirrhotic rats. <i>Hepatology</i> , <b>1995</b> , 21, 554-560	11.2	69
22	Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone, and norepinephrine levels. <i>Hepatology</i> , <b>1995</b> , 22, 479-87	11.2	33
21	Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. <i>Hepatology</i> , <b>1995</b> , 22, 915-920	11.2	42
20	Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. <i>Seminars in Liver Disease</i> , <b>1994</b> , 14, 44-58	7.3	62
19	Diagnosis of functional kidney failure of cirrhosis with Doppler sonography: prognostic value of resistive index. <i>Hepatology</i> , <b>1994</b> , 20, 839-44	11.2	101
18	Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. <i>Hepatology</i> , <b>1994</b> , 20, 948-54	11.2	48
17	Increased nitric oxide-dependent vasorelaxation in aortic rings of cirrhotic rats with ascites. <i>Hepatology</i> , <b>1994</b> , 20, 1615-21	11.2	77
16	Blunted natriuretic response to human urine extracts with Na <sup>+</sup> ,K <sup>(+)</sup> -ATPase inhibiting activity in experimental cirrhosis. <i>Journal of Hepatology</i> , <b>1994</b> , 20, 660-5	13.4	
15	Intracellular calcium concentration in vascular smooth muscle cells of rats with cirrhosis. <i>Journal of Hepatology</i> , <b>1994</b> , 21, 521-6	13.4	15
14	Circulating levels of endothelin in cirrhosis. <i>Gastroenterology</i> , <b>1993</b> , 104, 1485-91	13.3	168
13	Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. <i>Gastroenterology</i> , <b>1993</b> , 105, 229-36	13.3	661
12	Brachial and femoral artery blood flow in cirrhosis: Relationship to kidney dysfunction. <i>Hepatology</i> , <b>1993</b> , 17, 788-793	11.2	119
11	Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. <i>Hepatology</i> , <b>1993</b> , 17, 800-806	11.2	49
10	Impaired responsiveness to angiotensin II in experimental cirrhosis: Role of nitric oxide. <i>Hepatology</i> , <b>1993</b> , 18, 367-372	11.2	120

9	Carbon tetrachloride induced cirrhosis in rats: a useful tool for investigating the pathogenesis of ascites in chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>1992</b> , 7, 90-7	4	58
8	Pathogenesis of arterial hypotension in cirrhotic rats with ascites: role of endogenous nitric oxide. <i>Hepatology</i> , <b>1992</b> , 15, 343-9	11.2	179
7	Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. <i>Gastroenterology</i> , <b>1991</b> , 100, 494-501	13.3	68
6	Doses of endothelin have natriuretic effects in conscious rats with cirrhosis and ascites. <i>Kidney International</i> , <b>1991</b> , 40, 182-7	9.9	22
5	Temporal relationship between the decrease in arterial pressure and sodium retention in conscious spontaneously hypertensive rats with carbon tetrachloride induced cirrhosis. <i>Hepatology</i> , <b>1991</b> , 13, 585-589	11.2	31
4	Natriuretic hormone activity in the urine of cirrhotic patients. <i>Hepatology</i> , <b>1990</b> , 12, 467-75	11.2	17
3	Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. <i>Gastroenterology</i> , <b>1989</b> , 97, 1294-9	13.3	55
2	Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner		2
1	Experimental Models of Cirrhosis and Ascites 215-226		4